Literature DB >> 10352275

Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths.

D Shan1, O W Press, T T Tsu, M S Hayden, J A Ledbetter.   

Abstract

The heavy (VH) and light (VL) chain variable regions of the murine anti-human CD20 mAb 1F5 were cloned, and four single-chain Ab (scFv) molecules were constructed using linker peptides of variable lengths to join the VH and VL domains. Three constructs were engineered using linker peptides of 15, 10, and 5 aa residues consisting of (GGGGS)3, (GGGGS)2, and (GGGGS)1 sequences, respectively, whereas the fourth was prepared by joining the VH and VL domains directly. Each construct was fused to a derivative of human IgG1 (hinge plus CH2 plus CH3) to facilitate purification using staphylococcal protein A. The aggregation and CD20 binding properties of these four 1F5 scFv-Ig derivatives produced were investigated. Both size-exclusion HPLC column analysis and Western blots of proteins subjected to nonreducing SDS-PAGE suggested that all four 1F5 scFv-Ig were monomeric with m.w. of approximately 55 kDa. The CD20 binding properties of the four 1F5 scFv-Ig were studied by ELISA and flow cytometry. The 1F5 scFv-Ig with the 5-aa linker (GS1) demonstrated significantly superior binding to CD20-expressing target cells, compared with the other scFv-Ig constructs. Scatchard analysis of the radiolabeled monovalent GS1 scFv-Ig revealed a binding avidity of 1.35 x 108 M-1 compared with an avidity of 7.56 x 108 M-1 for the native bivalent 1F5 Ab. These findings suggest that the GS1 scFv-Ig with a short linker peptide of approximately 5 aa is the best of the engineered constructs for future studies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352275

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas.

Authors:  Natasha M Crosby; Mistuni Ghosh; Betty Su; Jennifer A Beckstead; Ayako Kamei; Jens B Simonsen; Bing Luo; Leo I Gordon; Trudy M Forte; Robert O Ryan
Journal:  Biochem Cell Biol       Date:  2015-04-20       Impact factor: 3.626

2.  Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.

Authors:  Y-Z Wang; F-F Tian; M Yan; J-M Zhang; Q Liu; J-Y Lu; W-B Zhou; H Yang; J Li
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

3.  Bioinformatics-led design of single-chain antibody molecules targeting DNA sequences for retinoblastoma.

Authors:  Guo-Gang Shang; Jian-Hua Zhang; Yong-Gang Lü; Jun Yun
Journal:  Int J Ophthalmol       Date:  2011-02-18       Impact factor: 1.779

4.  A pretargeted nanoparticle system for tumor cell labeling.

Authors:  Jonathan Gunn; Steven I Park; Omid Veiseh; Oliver W Press; Miqin Zhang
Journal:  Mol Biosyst       Date:  2010-11-24

5.  Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin.

Authors:  Sadaharu Matsushita; Victor Tuan Giam Chuang; Masanori Kanazawa; Sumio Tanase; Keiichi Kawai; Toru Maruyama; Ayaka Suenaga; Masaki Otagiri
Journal:  Pharm Res       Date:  2006-05-16       Impact factor: 4.200

6.  Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.

Authors:  Nathalie Scholler; Barbara Garvik; Martha Hayden-Ledbetter; Toni Kline; Nicole Urban
Journal:  Cancer Lett       Date:  2006-05-04       Impact factor: 8.679

7.  Analysis of the relationship between end-to-end distance and activity of single-chain antibody against colorectal carcinoma.

Authors:  Jianhua Zhang; Shanhong Liu; Zhigang Shang; Li Shi; Jun Yun
Journal:  Theor Biol Med Model       Date:  2012-08-22       Impact factor: 2.432

8.  Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.

Authors:  John M Pagel; Yukang Lin; Nathan Hedin; Anastasia Pantelias; Donald Axworthy; Diane Stone; Don K Hamlin; D Scott Wilbur; Oliver W Press
Journal:  Blood       Date:  2006-03-23       Impact factor: 22.113

9.  Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.

Authors:  Ryan B Craig; Christopher M Summa; Miriam Corti; Seth H Pincus
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

10.  Construction of miniantibodies for the in vivo study of human autoimmune diseases in animal models.

Authors:  Roberto Di Niro; Federica Ziller; Fiorella Florian; Sergio Crovella; Marco Stebel; Marco Bestagno; Oscar Burrone; Andrew R M Bradbury; Paola Secco; Roberto Marzari; Daniele Sblattero
Journal:  BMC Biotechnol       Date:  2007-08-01       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.